Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3878 - End of life (EOL) chemotherapy (CT) in gastro-intestinal (GI) cancer patients (pts): A retrospective AGEO study


09 Oct 2016


Poster display


Alexandra Lapeyre-Prost


Annals of Oncology (2016) 27 (6): 455-461. 10.1093/annonc/mdw384


A. Lapeyre-Prost1, G. Perkins1, M. Vallee2, A. Pozet3, D. Tougeron2, M. Maillet4, C. Locher5, J. Dreanic6, J.L. Legoux7, A. Lievre8, C. Lecaille9, J. Sabate10, F. Mary11, F. Bonnetain3, H. Jaulmes-Bouillot12, B. Landi1, J. Taieb1

Author affiliations

  • 1 Gi Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 2 Gastroenterology, CHU Poitiers, Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 3 Methodology And Quality Of Life In Oncology Unit, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 4 Gastroenterology, Hôpital St. Louis, Paris/FR
  • 5 Service Gastroentérologie, CH de Meaux, 77100 - Meaux/FR
  • 6 Gastroenterology, Hôpital Cochin, Paris/FR
  • 7 Hepato-gatroenterology And Digestive Oncology, C.H.R. Orleans - La Source, 45100 - Orleans/FR
  • 8 Medical Oncology, Institut Curie, St. Cloud/FR
  • 9 Hepato-gatroenterology And Digestive Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux/FR
  • 10 Gastroenterology, Hôpital Louis Mourier, Colombes/FR
  • 11 Gi Oncology, Hôpital Avicenne, Bobigny/FR
  • 12 Palliative Care Unit, Hopital European George Pompidou, Paris/FR


Abstract 3878


The use of CT during the EOL is poorly studied, with no dedicated study to GI cancer pts. Here, we report results of a retrospective study in this specific population, in the aim to analyze the factors associated to CT use within 3- and 1-month before death.


All pts that died from a GI cancer in 10 French tertiary care hospitals during 2014 were included in this retrospective cohort. Clinical (primary tumor, treatment history, performance status (PS)), demographical (age, sex, date and place of death) and biological (albumin level) data were collected and compared between pts receiving or not CT within 3- and 1-month before death. Overall survival (OS), defined as the time from diagnostic until death from any cause, was estimated using Kaplan Meier method. Univariate Cox regression's models were performed to estimate hazard ratio of all baseline variables with its 95% of confidence interval (CI).


437 pts were included in this study. All had a metastatic GI cancer (colorectal: 36.2%, pancreas: 28.4%, gastric: 10.3%, oesophageal: 9.8%, cholangiocarcinoma: 8.2%, hepatocarcinoma: 3.9%, others: 3.2%). Among them, 293 pts (67.0%) received CT within 3-months before death, and 144 (33.0%) did not, and 121 pts (27.7%) received CT within 1-month before death vs 316 (72.3%) who did not. Pts receiving CT within 3-months before death were significantly younger (median age: 65.5 vs 72.8 years, p 


In GI-cancer units, CT is given within 3- and 1- month before death, in two and one third of patients, respectively. Analysis of survivals together with a score aimed to drive treatment discontinuation decision will be presented at the meeting.

Clinical trial identification

Legal entity responsible for the study

Geraldine Perkins




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings